Slate Retail REIT Announces the Purchase of Mapleridge Center in Minnesota

TORONTO, ON—(Marketwired – June 28, 2017) – Slate Retail REIT (TSX: SRT.U) (TSX: SRT.UN) (the “REIT”), an owner and operator of U.S. grocery–anchored real estate, announced today that it has entered into a binding agreement to acquire Mapleridge Center (the “Property”) for U.S. $13.4 million ($117 per square foot). The Property is 89% occupied, is Rainbow Foods–anchored and is located in the Minneapolis–St. Paul Metropolitan Statistical Area. Closing is expected to be completed in the third quarter of 2017 and remains subject to customary closing conditions.

Slate Asset Management L.P. is the REIT's manager.

About Slate Retail REIT (TSX: SRT.U) (TSX: SRT.UN)
Slate Retail REIT is a real estate investment trust focused on U.S. grocery–anchored real estate. The REIT owns and operates over U.S. $1 billion of assets located across the top 50 U.S. metro markets that are visited regularly by consumers for their everyday needs. The REIT's conservative payout ratio, together with its diversified portfolio and quality tenant covenants, provides a strong basis to continue to grow unitholder distributions and the flexibility to capitalize on opportunities that drive value appreciation. Visit slateretailreit.com to learn more about the REIT.

About Slate Asset Management L.P.
Slate Asset Management L.P. is a leading real estate investment platform with over $4 billion in assets under management. Slate is a value–oriented manager and a significant sponsor of all of its private and publicly–traded investment vehicles, which are tailored to the unique goals and objectives of its investors. The firm's careful and selective investment approach creates long–term value with an emphasis on capital preservation and outsized returns. Slate is supported by exceptional people, flexible capital and a proven ability to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.

Global Pharma Companies Expect to Increase Percentage of Electronic TMF Documents to 88% by 2020

RESEARCH TRIANGLE PARK, NC—(Marketwired – June 28, 2017) – Life science firms are converting trial master file (TMF) documents into electronic formats, with 88% of surveyed global teams planning to shift to eTMFs by 2020, according to a study published by industry intelligence provider Cutting Edge Information.

Data from the study, Trial Master File Management: Uphold Documentation Processes to Safeguard Good Clinical Practices, revealed that the goal for U.S. clinical teams is to increase their percentage of electronic trial master files, or eTMFs, from an average of 38% to 75% by the year 2020. Surveyed clinical teams from the developed markets of the European Union (EU) estimate that an average of 45% of their TMFs are electronic currently, but they expect this balance to shift to over 75% by 2020.

However, country–level teams in emerging markets are anticipated to undergo the most dramatic change. On average, clinical teams from Brazil and India plan to increase their distribution of TMFs from 8% electronic and 92% paper documents to 77% electronic and 23% paper documents by 2020.

“Across the life sciences industry, clinical teams are increasingly moving toward the use of electronic trial master files,” said Sarah Ray, senior research analyst at Cutting Edge Information. “Once fully developed, these solutions will help reduce the paper associated with companies' TMF files and increase teamwide accessibility.”

Although many pharmaceutical companies have begun using electronic case report forms and electronic informed consent documents, some companies still remain reluctant to make this transition. Cutting Edge Information's study found that surveyed clinical teams may struggle with incorporating eTMF solutions with existing platforms because they consider wet ink signatures as a necessary part of their TMF.

However, FDA, MHRA and EMA agencies have stepped in and offered support for the use of digital signatures in lieu of wet ink signatures, making companies more comfortable with the change. Back in 2013, the FDA noted that official copies of source data — an essential TMF document — can be either paper or electronic. In 2015, the FDA also provided guidance for use of electronic informed consent within companies' clinical studies.

Trial Master File Management: Uphold Documentation Processes to Safeguard Good Clinical Practices, explores clinical team structures, responsibilities, as well as other trends associated with TMF management. The report, available at https://www.cuttingedgeinfo.com/product/trial–master–file–benchmarking/, guides clinical executives through trial master file management practices. Report highlights include:

  • Best practice recommendations and projected costs associated with implementing an eTMF platform
  • Benchmarking data on dedicated trial master file teams' staffing levels and necessary training structures
  • Metrics detailing clinical trial master file quality control processes, including the number and timing of checks performed on site and sponsor–level documents

For more information about Cutting Edge Information's clinical reports, please visit https://www.cuttingedgeinfo.com/product–category/clinical–development/.

Image Available: http://www.marketwire.com/library/MwGo/2017/6/26/11G141817/Images/June_28_2017_–_PH215_–_Global_Pharma_Companies_Exp–9d62ed2052a091b0ad62f4a82508bae5.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/6/26/11G141817/Images/June_28_2017_–_PH215_–_Global_Pharma_Companies_Exp–1f83f611bb0c9f38bbbf2c6d6a729474.jpg